Augmenting engineered T-cell strategies in solid cancers through epigenetic priming
| Autor: | Morten F. Gjerstorff, Aaraby Y. Nielsen, Sofie Traynor, Maria Ormhøj |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Adoptive cell transfer T cell T-Lymphocytes Immunology Receptors Antigen T-Cell Priming (immunology) Cancer immunotherapy Immunotherapy Adoptive Epigenesis Genetic Genetically modifed T cells 03 medical and health sciences 0302 clinical medicine Antigen SDG 3 - Good Health and Well-being Antigens Neoplasm Neoplasms Solid tumors Tumor Microenvironment Immunology and Allergy Medicine Animals Humans Epigenetics Combination therapy DNA Modification Methylases Tumor microenvironment business.industry T-cell receptor Combined Modality Therapy Chimeric antigen receptor Histone Deacetylase Inhibitors medicine.anatomical_structure Oncology Epigenetic drugs Cancer research Tumor Escape business Genetically modified T cells Cancer/testis antigens 030215 immunology |
| Zdroj: | Nielsen, A Y, Ormhøj, M, Traynor, S & Gjerstorff, M F 2020, ' Augmenting engineered T-cell strategies in solid cancers through epigenetic priming ', Cancer Immunology, Immunotherapy, vol. 69, pp. 2169–2178 . https://doi.org/10.1007/s00262-020-02661-1 Nielsen, A Y, Ormhøj, M, Traynor, S & Gjerstorff, M F 2020, ' Augmenting engineered T-cell strategies in solid cancers through epigenetic priming ', Cancer Immunology, Immunotherapy, vol. 69, no. 11, pp. 2169-2178 . https://doi.org/10.1007/s00262-020-02661-1 |
| ISSN: | 1432-0851 |
| Popis: | T-cell receptor (TCR)- and chimeric antigen receptor (CAR)-based adoptive cell transfer (ACT) has shown promising results in hematological malignancies, but remains immature in solid cancers. The challenges associated with identification of tumor-specific targets, the heterogenic antigen expression, limited T-cell trafficking to tumor sites and the hostile tumor microenvironment (TME), are all factors contributing to the limited efficacy of ACT therapies against solid tumors. Epigenetic priming of tumor cells and the microenvironment may be a way of overcoming these obstacles and improving the clinical efficacy of adoptive T-cell therapies in the future. Here, we review the current literature and suggest combining epigenetic modulators and ACT strategies as a way of augmenting the efficacy of TCR- and CAR-engineered T cells against solid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink